Symbols / BDTX
BDTX Chart
About
Black Diamond Therapeutics, Inc., a clinical-stage oncology company, focuses on the discovery and development of MasterKey therapies for patients with genetically defined tumors. The company's lead product candidate is BDTX-1535, a brain-penetrant epidermal growth factor receptor MasterKey inhibitor, which is in Phase 2 clinical trial for the treatment of epidermal growth factor receptor mutant non-small cell lung cancer, as well as Phase 1 clinical trial to treat glioblastoma. It is also developing BDTX-4933, a brain-penetrant RAF MasterKey inhibitor targeting KRAS, NRAS, and BRAF alterations in solid tumors that is in Phase 1 clinical trial. In addition, the company is developing BDTX-4876, a MasterKey inhibitor of oncogenic FGFR2/3 mutations with selectivity versus FGFR1/4, which is in preclinical stage. The company was formerly known as ASET Therapeutics, Inc. and changed its name to Black Diamond Therapeutics, Inc. in January 2018. Black Diamond Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Biotechnology | Market Cap | 150.13M |
| Enterprise Value | 29.45M | Income | 21.50M | Sales | 70.00M |
| Book/sh | 2.21 | Cash/sh | 2.38 | Dividend Yield | — |
| Payout | 0.00% | Employees | 24 | IPO | — |
| P/E | 7.12 | Forward P/E | -4.39 | PEG | — |
| P/S | 2.14 | P/B | 1.19 | P/C | — |
| EV/EBITDA | 1.95 | EV/Sales | 0.42 | Quick Ratio | 8.72 |
| Current Ratio | 8.94 | Debt/Eq | 15.59 | LT Debt/Eq | — |
| EPS (ttm) | 0.37 | EPS next Y | -0.60 | EPS Growth | — |
| Revenue Growth | — | Earnings | 2026-03-05 | ROA | 6.26% |
| ROE | 19.23% | ROIC | — | Gross Margin | 100.00% |
| Oper. Margin | 21.15% | Profit Margin | 30.71% | Shs Outstand | 56.97M |
| Shs Float | 45.95M | Short Float | 10.41% | Short Ratio | 4.49 |
| Short Interest | — | 52W High | 4.94 | 52W Low | 1.20 |
| Beta | 3.36 | Avg Volume | 1.09M | Volume | 314.18K |
| Target Price | $9.29 | Recom | Strong_buy | Prev Close | $2.55 |
| Price | $2.63 | Change | 3.33% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
$9.29
Mean price target
2. Current target
$2.55
Latest analyst target
3. DCF / Fair value
$3.24
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$2.55
Low
$6.00
High
$13.00
Mean
$9.29
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2026-01-16 | main | Piper Sandler | Overweight → Overweight | $8 |
| 2025-12-04 | down | Guggenheim | Buy → Neutral | — |
| 2025-09-04 | init | Guggenheim | — → Buy | $8 |
| 2025-08-11 | main | HC Wainwright & Co. | Buy → Buy | $10 |
| 2025-03-18 | main | HC Wainwright & Co. | Buy → Buy | $12 |
| 2025-03-07 | main | Stifel | Buy → Buy | $15 |
| 2024-11-06 | reit | HC Wainwright & Co. | Buy → Buy | $11 |
| 2024-10-09 | reit | HC Wainwright & Co. | Buy → Buy | $11 |
| 2024-10-08 | reit | Wedbush | Outperform → Outperform | $16 |
| 2024-09-24 | reit | HC Wainwright & Co. | Buy → Buy | $11 |
| 2024-09-23 | main | Piper Sandler | Overweight → Overweight | $15 |
| 2024-09-18 | reit | HC Wainwright & Co. | Buy → Buy | $11 |
| 2024-09-10 | reit | Wedbush | Outperform → Outperform | $16 |
| 2024-09-04 | reit | HC Wainwright & Co. | Buy → Buy | $11 |
| 2024-08-07 | reit | Wedbush | Outperform → Outperform | $16 |
| 2024-07-31 | init | Raymond James | — → Outperform | $20 |
| 2024-07-03 | main | Piper Sandler | Overweight → Overweight | $12 |
| 2024-06-07 | reit | HC Wainwright & Co. | Buy → Buy | $11 |
| 2024-05-16 | main | HC Wainwright & Co. | Buy → Buy | $11 |
| 2024-04-08 | main | Wedbush | Outperform → Outperform | $16 |
- BDTX Stock Hits 52 Week High: Is There More Room for Growth? - Yahoo Finance hu, 09 Oct 2025 07
- Should You Buy, Hold, or Sell BDTX Stock Ahead of Q3 Earnings? - Zacks Investment Research Fri, 31 Oct 2025 07
- Black Diamond Therapeutics: Underappreciated Despite An Upcoming Key Readout (NASDAQ:BDTX) - Seeking Alpha hu, 20 Nov 2025 08
- Would You Still Hold Black Diamond Therapeutics Stock If It Fell Another 30%? - Trefis ue, 23 Dec 2025 08
- Analyst Downgrades BDTX to Neutral from Buy | BDTX Stock News - GuruFocus hu, 04 Dec 2025 08
- New Analyst Forecast: $BDTX Given $8.0 Price Target - Quiver Quantitative hu, 16 Oct 2025 07
- Black Diamond Therapeutics (BDTX): Valuation Check After New Phase 2 Silevertinib Data and Glioblastoma Trial Plans - simplywall.st hu, 04 Dec 2025 08
- Stifel Reiterates Black Diamond Therapeutics (BDTX) Buy Recommendation - Nasdaq hu, 16 Oct 2025 07
- Is Black Diamond Therapeutics (BDTX) Stock Outpacing Its Medical Peers This Year? - Yahoo Finance Fri, 23 Jan 2026 08
- Black Diamond Therapeutics to Host Webcast on Phase 2 Clinical Trial Results of Silevertinib on December 3, 2025 - Quiver Quantitative ue, 02 Dec 2025 08
- Black Diamond Therapeutics, Inc. (BDTX) Hits Fresh High: Is There Still Room to Run? - Yahoo Finance Wed, 12 Nov 2025 08
- Declining Stock and Solid Fundamentals: Is The Market Wrong About Black Diamond Therapeutics, Inc. (NASDAQ:BDTX)? - Yahoo Finance Fri, 16 Jan 2026 08
- Black Diamond Therapeutics, Inc. (BDTX) Hit a 52 Week High, Can the Run Continue? - Yahoo Finance ue, 07 Oct 2025 07
- Has Black Diamond Therapeutics (BDTX) Outpaced Other Medical Stocks This Year? - Yahoo Finance Mon, 22 Sep 2025 07
- Down 30.5% in 4 Weeks, Here's Why You Should You Buy the Dip in Black Diamond (BDTX) - Yahoo Finance hu, 04 Dec 2025 08
Insider Transactions
| Date | Shares | Value | Url | Text | Insider | Position | Transaction | Start Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|
| 0 | 5208 | 14374 | — | Stock Award(Grant) at price 2.76 per share. | BEHBAHANI ALI | Director | — | 2025-12-12 00:00:00 | D |
| 1 | 4665 | 12875 | — | Stock Award(Grant) at price 2.76 per share. | RAMAN PRAKASH | Director | — | 2025-12-12 00:00:00 | D |
| 2 | 4291 | 14375 | — | Stock Award(Grant) at price 3.35 per share. | BEHBAHANI ALI | Director | — | 2025-09-19 00:00:00 | D |
| 3 | 3843 | 12874 | — | Stock Award(Grant) at price 3.35 per share. | RAMAN PRAKASH | Director | — | 2025-09-19 00:00:00 | D |
| 4 | 6170 | 14376 | — | Stock Award(Grant) at price 2.33 per share. | BEHBAHANI ALI | Director | — | 2025-06-20 00:00:00 | D |
| 5 | 5526 | 12876 | — | Stock Award(Grant) at price 2.33 per share. | RAMAN PRAKASH | Director | — | 2025-06-20 00:00:00 | D |
| 6 | 7646 | 14374 | — | Stock Award(Grant) at price 1.88 per share. | BEHBAHANI ALI | Director | — | 2025-03-21 00:00:00 | D |
| 7 | 6848 | 12874 | — | Stock Award(Grant) at price 1.88 per share. | RAMAN PRAKASH | Director | — | 2025-03-21 00:00:00 | D |
| 8 | 5784292 | 10712939 | — | Sale at price 1.72 - 2.00 per share. | BIOTECH GROWTH N.V. | Beneficial Owner of more than 10% of a Class of Security | — | 2025-03-19 00:00:00 | I |
| 9 | 75000 | — | — | Stock Award(Grant) at price 0.00 per share. | HATZIS-SCHOCH BRENT | Chief Operating Officer | — | 2025-01-30 00:00:00 | D |
Financials
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| TaxEffectOfUnusualItems | 0.00 | 0.00 | 0.00 | 0.00 |
| TaxRateForCalcs | 0.00 | 0.00 | 0.00 | 0.00 |
| NormalizedEBITDA | -78.44M | -86.02M | -94.55M | -126.67M |
| TotalUnusualItems | 0.00 | 2.23M | 0.00 | |
| TotalUnusualItemsExcludingGoodwill | 0.00 | 2.23M | 0.00 | |
| NetIncomeFromContinuingOperationNetMinorityInterest | -69.68M | -82.44M | -91.17M | -125.60M |
| ReconciledDepreciation | 343.00K | 437.00K | 508.00K | 205.00K |
| EBITDA | -78.44M | -86.02M | -92.32M | -126.67M |
| EBIT | -78.78M | -86.46M | -92.83M | -126.87M |
| NetInterestIncome | 2.18M | 1.92M | 2.03M | 3.46M |
| InterestExpense | 0.00 | |||
| InterestIncome | 2.18M | 1.92M | 2.03M | 3.46M |
| NormalizedIncome | -69.68M | -82.44M | -93.40M | -125.60M |
| NetIncomeFromContinuingAndDiscontinuedOperation | -69.68M | -82.44M | -91.17M | -125.60M |
| TotalExpenses | 78.78M | 86.46M | 92.83M | 126.87M |
| TotalOperatingIncomeAsReported | -78.78M | -86.46M | -92.83M | -126.87M |
| DilutedAverageShares | 55.03M | 43.95M | 36.23M | 36.19M |
| BasicAverageShares | 55.03M | 43.95M | 36.23M | 36.19M |
| DilutedEPS | -1.27 | -1.88 | -2.52 | -3.47 |
| BasicEPS | -1.27 | -1.88 | -2.52 | -3.47 |
| DilutedNIAvailtoComStockholders | -69.68M | -82.44M | -91.17M | -125.60M |
| NetIncomeCommonStockholders | -69.68M | -82.44M | -91.17M | -125.60M |
| NetIncome | -69.68M | -82.44M | -91.17M | -125.60M |
| NetIncomeIncludingNoncontrollingInterests | -69.68M | -82.44M | -91.17M | -125.60M |
| NetIncomeContinuousOperations | -69.68M | -82.44M | -91.17M | -125.60M |
| PretaxIncome | -69.68M | -82.44M | -91.17M | -125.60M |
| OtherIncomeExpense | 6.92M | 2.09M | -372.00K | -2.19M |
| OtherNonOperatingIncomeExpenses | 6.92M | 2.09M | -354.00K | -2.19M |
| SpecialIncomeCharges | 0.00 | 2.23M | 0.00 | |
| GainOnSaleOfPPE | 0.00 | 2.23M | 0.00 | |
| EarningsFromEquityInterest | 0.00 | -2.25M | 0.00 | |
| NetNonOperatingInterestIncomeExpense | 2.18M | 1.92M | 2.03M | 3.46M |
| InterestExpenseNonOperating | 0.00 | |||
| InterestIncomeNonOperating | 2.18M | 1.92M | 2.03M | 3.46M |
| OperatingIncome | -78.78M | -86.46M | -92.83M | -126.87M |
| OperatingExpense | 78.78M | 86.46M | 92.83M | 126.87M |
| ResearchAndDevelopment | 51.31M | 59.35M | 64.44M | 96.83M |
| SellingGeneralAndAdministration | 27.47M | 27.11M | 28.39M | 30.04M |
| GeneralAndAdministrativeExpense | 27.47M | 27.11M | 28.39M | 30.04M |
| OtherGandA | 27.47M | 27.11M | 28.39M | 30.04M |
| TotalRevenue | 0.00 | 0.00 | 0.00 | 0.00 |
| OperatingRevenue | 0.00 | 0.00 | 0.00 | 0.00 |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| OrdinarySharesNumber | 56.64M | 51.65M | 36.43M | 36.23M |
| ShareIssued | 56.64M | 51.65M | 36.43M | 36.23M |
| TotalDebt | 22.19M | 25.30M | 28.14M | 28.46M |
| TangibleBookValue | 83.28M | 116.74M | 115.69M | 195.90M |
| InvestedCapital | 83.28M | 116.74M | 115.69M | 195.90M |
| WorkingCapital | 80.60M | 114.39M | 112.44M | 192.06M |
| NetTangibleAssets | 83.28M | 116.74M | 115.69M | 195.90M |
| CapitalLeaseObligations | 22.19M | 25.30M | 28.14M | 28.46M |
| CommonStockEquity | 83.28M | 116.74M | 115.69M | 195.90M |
| TotalCapitalization | 83.28M | 116.74M | 115.69M | 195.90M |
| TotalEquityGrossMinorityInterest | 83.28M | 116.74M | 115.69M | 195.90M |
| StockholdersEquity | 83.28M | 116.74M | 115.69M | 195.90M |
| GainsLossesNotAffectingRetainedEarnings | 24.00K | -27.00K | -1.82M | -414.00K |
| OtherEquityAdjustments | 24.00K | -27.00K | -1.82M | -414.00K |
| RetainedEarnings | -487.11M | -417.43M | -334.99M | -243.82M |
| AdditionalPaidInCapital | 570.36M | 534.19M | 452.50M | 440.13M |
| CapitalStock | 7.00K | 7.00K | 5.00K | 5.00K |
| CommonStock | 7.00K | 7.00K | 5.00K | 5.00K |
| PreferredStock | 0.00 | 0.00 | 0.00 | 0.00 |
| TotalLiabilitiesNetMinorityInterest | 39.35M | 41.83M | 40.56M | 51.78M |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 18.78M | 22.18M | 25.30M | 28.14M |
| LongTermDebtAndCapitalLeaseObligation | 18.78M | 22.18M | 25.30M | 28.14M |
| LongTermCapitalLeaseObligation | 18.78M | 22.18M | 25.30M | 28.14M |
| CurrentLiabilities | 20.57M | 19.65M | 15.26M | 23.64M |
| CurrentDebtAndCapitalLeaseObligation | 3.40M | 3.11M | 2.84M | 320.00K |
| CurrentCapitalLeaseObligation | 3.40M | 3.11M | 2.84M | 320.00K |
| PayablesAndAccruedExpenses | 17.17M | 16.53M | 12.42M | 23.32M |
| CurrentAccruedExpenses | 13.16M | 14.21M | 10.54M | 19.21M |
| Payables | 4.01M | 2.32M | 1.88M | 4.11M |
| AccountsPayable | 4.01M | 2.32M | 1.88M | 4.11M |
| TotalAssets | 122.64M | 158.57M | 156.25M | 247.68M |
| TotalNonCurrentAssets | 21.46M | 24.53M | 28.55M | 31.98M |
| OtherNonCurrentAssets | 1.07M | 823.00K | 1.17M | 1.24M |
| NetPPE | 20.40M | 23.71M | 27.38M | 30.74M |
| AccumulatedDepreciation | -1.14M | -799.00K | -750.00K | -369.00K |
| GrossPPE | 21.54M | 24.51M | 28.13M | 31.11M |
| Leases | 2.51M | 2.51M | 2.51M | 2.44M |
| ConstructionInProgress | 0.00 | 148.00K | ||
| OtherProperties | 19.01M | 21.98M | 25.56M | 28.39M |
| MachineryFurnitureEquipment | 17.00K | 17.00K | 55.00K | 137.00K |
| Properties | 0.00 | 0.00 | 0.00 | 0.00 |
| CurrentAssets | 101.18M | 134.03M | 127.71M | 215.70M |
| OtherCurrentAssets | 2.60M | 2.63M | 4.90M | 5.92M |
| PrepaidAssets | 5.92M | |||
| CashCashEquivalentsAndShortTermInvestments | 98.58M | 131.40M | 122.81M | 209.79M |
| OtherShortTermInvestments | 62.14M | 75.18M | 88.49M | 143.99M |
| CashAndCashEquivalents | 36.44M | 56.22M | 34.31M | 65.80M |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| FreeCashFlow | -62.30M | -66.75M | -85.27M | -102.86M |
| IssuanceOfCapitalStock | 24.49M | 71.85M | 0.00 | 0.00 |
| CapitalExpenditure | -33.00K | -192.00K | -2.71M | |
| EndCashPosition | 37.26M | 57.04M | 35.48M | 67.02M |
| BeginningCashPosition | 57.04M | 35.48M | 67.02M | 35.83M |
| ChangesInCash | -19.79M | 21.56M | -31.54M | 31.19M |
| FinancingCashFlow | 25.55M | 71.93M | 177.00K | 729.00K |
| CashFlowFromContinuingFinancingActivities | 25.55M | 71.93M | 177.00K | 729.00K |
| ProceedsFromStockOptionExercised | 1.05M | 82.00K | 177.00K | 729.00K |
| NetCommonStockIssuance | 24.49M | 71.85M | 0.00 | 0.00 |
| CommonStockIssuance | 24.49M | 71.85M | 0.00 | 0.00 |
| InvestingCashFlow | 16.97M | 16.35M | 53.37M | 130.61M |
| CashFlowFromContinuingInvestingActivities | 16.97M | 16.35M | 53.37M | 130.61M |
| NetInvestmentPurchaseAndSale | 16.87M | 16.28M | 53.55M | 133.32M |
| SaleOfInvestment | 139.75M | 78.17M | 113.69M | 182.83M |
| PurchaseOfInvestment | -122.88M | -61.89M | -60.14M | -49.51M |
| NetPPEPurchaseAndSale | 94.00K | 62.00K | -183.00K | -2.71M |
| SaleOfPPE | 94.00K | 95.00K | 9.00K | 0.00 |
| PurchaseOfPPE | 0.00 | -33.00K | -192.00K | -2.71M |
| OperatingCashFlow | -62.30M | -66.72M | -85.08M | -100.15M |
| CashFlowFromContinuingOperatingActivities | -62.30M | -66.72M | -85.08M | -100.15M |
| ChangeInWorkingCapital | -2.69M | 3.69M | -9.90M | 7.02M |
| ChangeInOtherCurrentLiabilities | -3.40M | -3.11M | -2.84M | -1.73M |
| ChangeInOtherCurrentAssets | -249.00K | 0.00 | 16.00K | 90.00K |
| ChangeInPayablesAndAccruedExpense | 927.00K | 4.54M | -8.09M | 10.28M |
| ChangeInAccruedExpense | -756.00K | 3.94M | -5.86M | 8.71M |
| ChangeInPayable | 1.68M | 597.00K | -2.23M | 1.57M |
| ChangeInAccountPayable | 1.68M | 597.00K | -2.23M | 1.57M |
| ChangeInPrepaidAssets | 33.00K | 2.27M | 1.02M | -1.63M |
| OtherNonCashItems | 2.97M | 2.81M | 2.73M | 2.01M |
| StockBasedCompensation | 10.63M | 9.60M | 12.20M | 14.04M |
| AmortizationOfSecurities | -3.78M | -1.17M | 536.00K | 2.19M |
| DepreciationAmortizationDepletion | 343.00K | 437.00K | 508.00K | 205.00K |
| DepreciationAndAmortization | 343.00K | 437.00K | 508.00K | 205.00K |
| Depreciation | 343.00K | 437.00K | 508.00K | 205.00K |
| OperatingGainsLosses | -94.00K | 358.00K | 17.00K | -7.00K |
| EarningsLossesFromEquityInvestments | 0.00 | 2.25M | 0.00 | |
| GainLossOnInvestmentSecurities | -10.00K | |||
| GainLossOnSaleOfPPE | -94.00K | 358.00K | -2.23M | 3.00K |
| NetIncomeFromContinuingOperations | -69.68M | -82.44M | -91.17M | -125.60M |
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
Public Trades for BDTX
| Date | User | Asset | Broker | Type | Position Size | Entry Price | Patterns |
|---|